Technical Analysis for LPCN - Lipocine Inc.

Grade Last Price % Change Price Change
grade F 1.57 -1.26% -0.02
LPCN closed down 1.26 percent on Friday, May 24, 2019, on 26 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical LPCN trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish -1.26%
Lower Bollinger Band Walk Weakness -1.26%
Below Lower BB Weakness -1.26%
Lower Bollinger Band Touch Weakness -1.26%
Oversold Stochastic Weakness -1.26%

Older signals for LPCN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Chemistry Health Pharmaceutical Pharmaceutical Products Clinical Trial Alcohols Design Of Experiments Clinical Research Bypass Ketones Androstanes Testosterone Testosterone Replacement Therapy
Is LPCN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.64
52 Week Low 1.04
Average Volume 205,868
200-Day Moving Average 1.6275
50-Day Moving Average 1.9751
20-Day Moving Average 1.7955
10-Day Moving Average 1.7409
Average True Range 0.1202
ADX 30.31
+DI 12.7728
-DI 32.8477
Chandelier Exit (Long, 3 ATRs ) 1.6394
Chandelier Exit (Short, 3 ATRs ) 1.7906
Upper Bollinger Band 2.0286
Lower Bollinger Band 1.5624
Percent B (%b) 0.02
BandWidth 25.964912
MACD Line -0.0891
MACD Signal Line -0.0625
MACD Histogram -0.0266
Fundamentals Value
Market Cap 32.31 Million
Num Shares 20.6 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -1.69
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.71
Resistance 3 (R3) 1.71 1.68 1.68
Resistance 2 (R2) 1.68 1.64 1.67 1.67
Resistance 1 (R1) 1.62 1.62 1.65 1.62 1.67
Pivot Point 1.59 1.59 1.60 1.58 1.59
Support 1 (S1) 1.53 1.55 1.56 1.53 1.47
Support 2 (S2) 1.50 1.53 1.49 1.47
Support 3 (S3) 1.44 1.50 1.46
Support 4 (S4) 1.44